DataBrief : Achieve Life Sciences Inc.
Achieve Life Sciences is a specialtypharmaceutical company committed to advancing
cytisinicline as a smoking cessation aid to address
the global tobacco and nicotine addiction
epidemic. Cytisinicline (also known as cytisine) is a
plant-based alkaloid with a high binding affinity to
the α4β2 nicotine receptor.
Growing confidence in a replacement for the
expiring Pfizer anti smoking drug plus a succesful
New Zealand clinical trial have lifted prospects for
Achieve. Institutional holders have increased from
9 to 15 in the December quarter.
Independent Investment Research, "IIR", is an independent investment research house based in Australia and the United States. IIR specialises in the analysis of high quality commissioned research for Brokers, Family Offices and Fund Managers. IIR distributes its research in Asia, United States and the Americas. IIR does not participate in any corporate or capital raising activity and therefore it does not have any inherent bias that may result from research that is linked to any corporate/ capital raising activity.
IIR was established in 2004 under Aegis Equities Research Group of companies to provide investment research to a select group of retail and wholesale clients. Since March 2010, IIR (the Aegis Equities business was sold to Morningstar) has operated independently from Aegis by former Aegis senior executives/shareholders to provide clients with unparalleled research that covers listed and unlisted managed investments, listed companies, structured products, and IPO's.
IIR takes great pride in the quality and independence of our analysis, underpinned by high caliber staff and a transparent, proven and rigorous research methodology.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.